<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16</volume><submitter>Ren L</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Although the transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab improves outcomes in unresectable HCC (uHCC), predictive tools are lacking. This study developed and validated a prognostic model for triple therapy efficacy.&lt;h4>Methods&lt;/h4>A multicenter study enrolled uHCC patients receiving TACE-sintilimab-bevacizumab. Overall survival (OS) was the primary endpoint; a Cox model was developed and validated.&lt;h4>Results&lt;/h4>This study enrolled 147 patients (training cohort: n = 92; validation cohort: n = 55). The optimal cutoff value for the fibrin degradation product-to-cholinesterase ratio*1000 (FCR) was determined as 0.8. Univariate and multivariate Cox regression analyses identified FCR, AST, AFP, and PVTT as independent OS predict</pubmed_abstract><journal>Frontiers in immunology</journal><pagination>1692632</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12685804</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.</pubmed_title><pmcid>PMC12685804</pmcid><pubmed_authors>She S</pubmed_authors><pubmed_authors>Ren L</pubmed_authors><pubmed_authors>Fei R</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Liao W</pubmed_authors><pubmed_authors>Cong X</pubmed_authors><pubmed_authors>Gao J</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors><pubmed_authors>Chen D</pubmed_authors><pubmed_authors>Mu S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.</name><description>&lt;h4>Introduction&lt;/h4>Although the transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab improves outcomes in unresectable HCC (uHCC), predictive tools are lacking. This study developed and validated a prognostic model for triple therapy efficacy.&lt;h4>Methods&lt;/h4>A multicenter study enrolled uHCC patients receiving TACE-sintilimab-bevacizumab. Overall survival (OS) was the primary endpoint; a Cox model was developed and validated.&lt;h4>Results&lt;/h4>This study enrolled 147 patients (training cohort: n = 92; validation cohort: n = 55). The optimal cutoff value for the fibrin degradation product-to-cholinesterase ratio*1000 (FCR) was determined as 0.8. Univariate and multivariate Cox regression analyses identified FCR, AST, AFP, and PVTT as independent OS predict</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-06T00:26:05.399Z</modification><creation>2026-05-24T03:11:13.639Z</creation></dates><accession>S-EPMC12685804</accession><cross_references><pubmed>41376633</pubmed><doi>10.3389/fimmu.2025.1692632</doi></cross_references></HashMap>